Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

BALVERSA® (erdafitinib)

Medical Information

+ Save link

BALVERSA - ANNAR Study

Last Updated: 07/31/2024

SUMMARY

ANNAR (NCT03955913) is a prospective, non-interventional study to identify adult patients with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue and to assess eligibility status for BALVERSA studies. The primary data source for this study will be the patients’ medical records. Results from the ANNAR study have not been published. The study has enrolled 3679 patients from 199 study sites.¹ For complete study details, refer to https://clinicaltrials.gov/study/NCT03955913.

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) conducted on 29 July 2024 did not identify any relevant citations pertaining to this topic.

References

Show

Janssen Research & Development LLC. A study to identify participants with urothelial cancer and fibroblast growth factor receptor gene aberrations. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2024 July 29]. Available from: https://clinicaltrials.gov/study/NCT03955913. NLM Identifier: NCT03955913.